Zyden Gentec Peer Comparison

BSE: 530091

₹0.87

₹-0.04 (-4.40%)

As on 28-Mar-2016IST

Market cap

₹5 Cr

Revenue (TTM)

₹1 Cr

P/E Ratio

--

P/B Ratio

0.4

Div. Yield

0 %

Edit

	Zyden Gentec	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	5	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	1	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-3.77	414.00	288.22	-371.81	387.35
Net Margin (%)	-329.02	11.23	14.79	-3.93	26.01
RoE (%)	-47.91	8.38	29.77	-3.85	25.18
Price to Earnings	--	78.49	103.71	--	69.57
Price-To-Book	0.37	6.38	22.27	3.64	15.55

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Zyden Gentec	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	1.15	3,565.84	153.79	--	238.51
Total Income	1.15	3,586.86	160.15	--	238.90
Total Expenditure	1.58	3,604.32	122.14	--	196.43
EBITDA	-0.43	-38.48	31.65	--	42.08
Depreciation	--	163.95	8.26	--	2.60
EBIT	-0.43	-202.43	23.39	--	39.48
Interest	0.00	265.14	2.61	--	4.75
Other Income	0.00	21.02	6.36	--	0.38
Exceptional Items	-3.34	--	--	--	--
Profit before Tax	-3.77	-446.55	27.14	--	35.11
Provision for Tax	--	-134.76	8.71	--	11.82
Profit after Tax	-3.77	-311.79	18.43	--	23.30

Liabilities (₹ Cr)

	Zyden Gentec	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	5.98	2,674.80	196.86	--	82.22
Minority Interest	--	329.83	--	--	--
Non-Current Liabilities	0.00	1,702.75	30.75	--	25.37
Current Liabilities	2.14	2,863.66	68.83	--	105.56
Total Liabilities	8.12	7,813.24	296.44	--	213.15

Assets (₹ Cr)

	Zyden Gentec	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	7.40	4,756.39	131.06	--	85.41
Current Assets	0.73	2,814.65	165.38	--	124.10
Total Assets	8.12	7,813.24	296.44	--	213.15
Total Debt*	2.01	3,374.60	49.52	--	53.91
Net Current Assets	-1.41	-49.01	96.56	--	18.54
Contingent Liabilities	0.02	473.19	0.48	--	0.08

Cashflow (₹ Cr)

	Zyden Gentec	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	0.09	183.32	-13.77	--	14.84
Cash Flow from Investing Activities	2.41	94.57	4.25	--	-20.87
Cash from Financing Activities	-2.53	-776.45	16.43	--	5.62
Net Cash Inflow / Outflow	-0.03	-498.56	6.91	--	-0.41

Ratios

Profitability Ratios

	Zyden Gentec	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-33.84	-2.87	13.09	--	34.33
ROE (%)	-47.91	-11.43	9.82	--	34.64
ROA (%)	-32.82	-4.01	7.04	--	12.64
EBIT Margin (%)	-37.63	-0.49	24.71	--	17.80
Net Margin (%)	-329.02	-8.69	11.51	--	9.75
Cash Profit Margin (%)	-329.30	-4.15	17.35	--	10.86

Growth Ratios

	Zyden Gentec	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	54.29	-9.43	135.95	--	26.72
EBIT Growth (%)	15.64	-114.30	326.10	--	26.85
Net Profit Growth (%)	-72.66	53.24	8,583.73	--	25.95
EPS Growth (%)	-72.66	68.03	8,583.73	--	25.51
Book Value Growth (%)	-38.65	-6.14	10.33	--	40.52

Valuation Ratios

	Zyden Gentec	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	0.00	0.00	--	0.00
Price / Book Value	0.00	1.86	0.00	--	0.00
Dividend Yield (%)	--	0.00	--	--	--
EV/EBITDA	-30.44	-448.40	1.14	--	1.51
Market Cap (₹ Cr)	0.00	4,903.12	0.00	--	0.00

Solvency Ratios

	Zyden Gentec	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.34	1.28	0.25	--	0.69
Short term debt to equity ratio	0.34	0.21	0.07	--	0.32
Current Ratio	0.34	0.98	2.40	--	1.18
Quick Ratio	0.34	0.70	2.12	--	0.81
Interest Coverage	0.00	-0.68	11.39	--	8.39

Operating Efficiency Ratios

	Zyden Gentec	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	63.44	35.73	54.90	--	31.90
Asset Turnover	0.10	0.46	0.59	--	1.29
Receivable days	803.05	114.46	144.39	--	96.45
Inventory Days	0.00	85.73	39.59	--	50.55
Payable days	17.29	160.83	158.53	--	142.81
Cash Conversion Cycle	785.76	39.36	25.45	--	4.19